200 related articles for article (PubMed ID: 19369642)
1. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
Proust-Lima C; Taylor JM
Biostatistics; 2009 Jul; 10(3):535-49. PubMed ID: 19369642
[TBL] [Abstract][Full Text] [Related]
2. A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial.
Parr H; Porta N; Tree AC; Dearnaley D; Hall E
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1055-1068. PubMed ID: 36822374
[TBL] [Abstract][Full Text] [Related]
3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
4. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
5. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?
Kuban DA; El-Mahdi AM; Schellhammer PF
Semin Radiat Oncol; 1998 Apr; 8(2):72-80. PubMed ID: 9516587
[TBL] [Abstract][Full Text] [Related]
6. Real-time individual predictions of prostate cancer recurrence using joint models.
Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
11. Joint models for dynamic prediction in localised prostate cancer: a literature review.
Parr H; Hall E; Porta N
BMC Med Res Methodol; 2022 Sep; 22(1):245. PubMed ID: 36123621
[TBL] [Abstract][Full Text] [Related]
12. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model.
Fiorino C; Broggi S; Fossati N; Cozzarini C; Goldner G; Wiegel T; Hinkelbein W; Karnes RJ; Boorjian SA; Haustermans K; Joniau S; Palorini F; Shariat S; Montorsi F; Van Poppel H; Di Muzio N; Calandrino R; Briganti A
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):333-340. PubMed ID: 27497691
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer.
Vollmer RT; Montana GS
Clin Cancer Res; 1999 Dec; 5(12):4119-25. PubMed ID: 10632349
[TBL] [Abstract][Full Text] [Related]
15. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.
Proust-Lima C; Taylor JM; Williams SG; Ankerst DP; Liu N; Kestin LL; Bae K; Sandler HM
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):782-91. PubMed ID: 19014779
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.
McLean M; Panzarella T; Warde PR; Gospodarowicz M; Duncan W; Catton C; Bissett R
Clin Oncol (R Coll Radiol); 1997; 9(4):226-33. PubMed ID: 9315396
[TBL] [Abstract][Full Text] [Related]
18. Joint latent class models for longitudinal and time-to-event data: a review.
Proust-Lima C; Séne M; Taylor JM; Jacqmin-Gadda H
Stat Methods Med Res; 2014 Feb; 23(1):74-90. PubMed ID: 22517270
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
Kuban DA; el-Mahdi AM; Schellhammer PF
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
